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Abstract
In heart failure (HF), arrhythmogenic spontaneous sarcoplasmic reticulum (SR) Ca
2+ release and afterdepolarizations in
cardiac myocytes have been linked to abnormally high activity of ryanodine receptors (RyR2s) associated with enhanced
phosphorylation of the channel. However, the specific molecular mechanisms underlying RyR2 hyperphosphorylation in HF
remain poorly understood. The objective of the current study was to test the hypothesis that the enhanced expression of
muscle-specific microRNAs (miRNAs) underlies the HF-related alterations in RyR2 phosphorylation in ventricular myocytes
by targeting phosphatase activity localized to the RyR2. We studied hearts isolated from canines with chronic HF exhibiting
increased left ventricular (LV) dimensions and decreased LV contractility. qRT-PCR revealed that the levels of miR-1 and miR-
133, the most abundant muscle-specific miRNAs, were significantly increased in HF myocytes compared with controls (2-
and 1.6-fold, respectively). Western blot analyses demonstrated that expression levels of the protein phosphatase 2A (PP2A)
catalytic and regulatory subunits, which are putative targets of miR-133 and miR-1, were decreased in HF cells. PP2A
catalytic subunit mRNAs were validated as targets of miR-133 by using luciferase reporter assays. Pharmacological inhibition
of phosphatase activity increased the frequency of diastolic Ca
2+ waves and afterdepolarizations in control myocytes. The
decreased PP2A activity observed in HF was accompanied by enhanced Ca
2+/calmodulin-dependent protein kinase
(CaMKII)-mediated phosphorylation of RyR2 at sites Ser-2814 and Ser-2030 and increased frequency of diastolic Ca
2+ waves
and afterdepolarizations in HF myocytes compared with controls. In HF myocytes, CaMKII inhibitory peptide normalized the
frequency of pro-arrhythmic spontaneous diastolic Ca
2+ waves. These findings suggest that altered levels of major muscle-
specific miRNAs contribute to abnormal RyR2 function in HF by depressing phosphatase activity localized to the channel,
which in turn, leads to the excessive phosphorylation of RyR2s, abnormal Ca
2+ cycling, and increased propensity to
arrhythmogenesis.
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Introduction
Heart failure (HF) remains a leading cause of mortality and
approximately 50% of HF patients die suddenly as a result of
ventricular tachyarrhythmias stemming from the increased
propensity of ventricular myocytes to generate delayed and/or
early afterdepolarizations [1,2]. The generation of arrhythmogenic
afterdepolarizations in HF has been linked to extrasystolic
spontaneous Ca
2+ release from the sarcoplasmic reticulum (SR)
[3,4,5,6,7]. It is believed that the increased occurrence of
spontaneous Ca
2+ release in ventricular myocytes corresponds to
the abnormally high activity of ryanodine receptors (RyR2s), the
SR Ca
2+ release channels [8,9]. Studies investigating the RyR2
properties in HF have consistently reported enhanced phosphor-
ylation of the RyR2 either at the cAMP-dependent protein kinase
A (PKA) site S-2808 [10] and/or at the Ca
2+/calmodulin-
dependent protein kinase (CaMKII) site Ser-2814 [11]. However,
the molecular events leading to RyR2 hyperphosphorylation in
HF remain uncertain [12,13].
In general, enhanced phosphorylation can be explained by the
increased activity of kinases and/or the decreased activity of
phosphatases in the vicinity of the channel. Two phosphatases
have been shown to scaffold to the RyR2 complex, PP1 and PP2A.
While PP1 has been identified as the phosphatase controlling
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28324RyR2 phosphorylation at the PKA site Ser-2808 [14], PP2A
appears to regulate the phosphorylation state of RyR2 at the
CaMKII site Ser-2814 and at a second PKA site Ser-2030 [14,15].
In HF, decreases in phosphatases PP1 and PP2A scaffolded to
RyR2 has been suggested as an underlying cause for hyperpho-
sphorylation of RyR2 at the PKA Ser-2808 [10] or the CaMKII
Ser-2814 sites [11].
We have previously reported that phosphatase activity in the
vicinity of the RyR2 channel can be regulated by the muscle-
specific microRNA (miRNA) 1 (miR-1) [16]. miRNAs are a newly
described class of regulators of cellular function that inhibit gene
expression by targeting messenger RNAs (mRNAs) for transla-
tional repression or cleavage [17,18]. We demonstrated that
adenovirally-mediated overexpression of miR-1 promotes arrhyth-
mogenic spontaneous Ca
2+ release and increases CaMKII-
dependent phosphorylation of RyR2 by targeting the regulatory
subunit of PP2A B56a [16]. Another regulatory subunit of PP2A
known to tether the PP2A catalytic subunit to the RyR2 complex,
B56d was recently validated as a target for miR-133, the second
most abundant miRNA in the heart [19]. Importantly, many
studies [20,21,22,23,24,25,26,27] have demonstrated that the
expression patterns of miRNAs are substantially altered in a
number of cardiac diseases, including HF. In the present study, we
utilized a canine model of nonischemic HF to test the hypothesis
that the HF-related changes in RyR2 phosphorylation levels were
mediated by the disruption of phosphatase activity localized to
RyR2s due to enhanced expression of the two most abundant
muscle-specific miRNAs, miR-1 and miR-133 [28].
Results
Pharmacological inhibition of phosphatase activity in
control myocytes promotes diastolic spontaneous Ca
2+
waves and delayed afterdepolarizations in the presence
of the b-adrenergic agonist isoproterenol
First, we examined whether or not inhibition of phosphatase
activity would result in the enhanced propensity of control
ventricular myocytes toward generation of Ca
2+-dependent after-
depolarizations. To examine the effects of reduced phosphatase
activity on Ca
2+ cycling and membrane potential, the PP1 and
PP2A inhibitor Calyculin A [29] (100 nM, 30 min pre-incubation)
was used. Control cells stimulated only with the b-adrenergic
agonist, isoproterenol (Iso), displayed a moderate frequency of
diastolic spontaneous Ca
2+ waves (SCW) and delayed after-
depolarizations (DADs) (Fig. 1). However, myocytes pretreated
with Calyculin A and subsequently stimulated with Iso resulted in
a significant increase (,six fold) in the rate of diastolic Ca
2+ waves
and DADs. The frequency of SCWs and DADs in myocytes
treated with Calyculin A alone did not significantly differ from that
observed with Iso alone. Taken together these results suggest that
phosphatase activity plays a critical role in controlling the stability
of intracellular Ca
2+ cycling.
HF myocytes display increased levels of muscle-specific
miR-1 and miR-133 and decreased levels of their
respective targets, regulatory (B56a and B56d and
catalytic subunits of PP2A
HF was characterized by increased LV chamber dimensions
and reduced LV fractional shortening (Fig. 2). Analysis using
quantitative RT-PCR revealed that the levels of mature miR-1
and -133 were significantly increased in myocytes isolated from
failing hearts when compared with controls (Fig. 3A and 3B).
Western blot analysis of B56a and B56d regulatory and catalytic
subunits of PP2A, which are putative targets of miR-1 and -133
(http://www.targetscan.org), showed significant decreases in
expression levels in HF vs. control myocytes (Fig. 3C,D,E,F).
Consistent with the observed decrease in protein levels, total PP2A
activity was also significantly reduced (30%) in HF when
compared with controls (Fig. 3G). Additionally, immunoprecipi-
tation studies demonstrated that the levels of B56a and PP2A
catalytic subunits scaffolded to RyR2s were significantly decreased
(i.e. ,40% and 60% of control values respectively, Fig. 3H,I,J).
Notably, CaMKII activity localized to RyR2s was not changed in
HF (Fig. 3K). Targeting of the PP2A catalytic a and b subunits by
miR-133 was validated using a 39-untranslated region (39-UTR)
luciferase reporter assay (Fig. 4A,B). To test whether or not PP2A
inhibition was sufficient to promote spontaneous Ca
2+ release,
myocytes were treated with a specific PP2A inhibitor, fostriecin
[30]. Preincubation of myocytes with fostriecin and subsequent
stimulation with Iso significantly enhanced the propensity of field-
stimulated myocytes to generate pro-arrhythmic spontaneous Ca
2+
waves. (Fig. 5A,B).
Using phosphospecific antibodies we assessed the phosphoryla-
tion state of RyR2s in HF vs. control myocytes at three different
sites, and found no changes in the RyR2 phosphorylation state at
the PKA site Ser-2808. However, a 3.5-fold increase in
Figure 1. Inhibition of phosphatase activity is sufficient to promote arrhythmogenic spontaneous Ca
2+ waves in normal paced
myocytes during beta-adrenergic stimulation. A. Representative confocal Ca
2+ images, with corresponding time dependent profiles (bottom)
and membrane potential recordings (top) in control myocytes at basal conditions, preincubated with 100 nM Calyculin A for 30 min, incubated with
100 nM isoproterenol for 3 min (Iso) and challenged with Iso after 30 min incubation with Calyculin A. B. Pooled data for a number of delayed after-
depolarizations due to spontaneous Ca
2+ waves per cycle. Basal SCW frequency was 0 out of 9 cells. Statistically significant at p,0.05, vs. * Calyculin A
and { vs Iso, n=5.
doi:10.1371/journal.pone.0028324.g001
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fold increase in phosphorylation at Ser-2030 in HF myocytes
(Fig. 6A and 6B). Consistent with previous reports [14], site Ser-
2030 phosphorylation by PKA in response to Iso stimulation was
partial (Fig. 6C,D). Therefore, to achieve maximal site Ser-2030
phosphorylation, treatment with Iso must be complemented by
Figure 2. Heart failure animals have increased LV chamber size and reduced fractional shortening. A. LV internal diameter- end diastole
is increased in the 4 month HF dogs. B. LV internal diameter- end systole is increased in the 4 month HF dogs. C. LV fractional shortening is reduced in
the 4 month HF dogs. *p,0.05, n=5–6.
doi:10.1371/journal.pone.0028324.g002
Figure 3. Changes in Expression Levels of miR-1 and miR-133 and their targets in canine HF Myocytes. A, B. Normalized levels of miR-1
and -133 assessed with qRT-PCR. *p,0.05, n=5. C. Representative Western blots of putative targets of miR-1 and -133, regulatory subunits B56a,
B56d and catalytic subunit of PP2A respectively. D,E,F. Normalized optical density (OD) for B56a, B65d and catalytic subunit of PP2A respectively;
*p,0.05, n=8. Note that anti-PP2AC antibody recognizes both a and b isoforms. G. Total PP2A activity is samples prepared from LV tissues of normal
and failing hearts, *p,0.05, n=4. H,I,J. Decrease in levels of PP2A scaffolded to RyR2 tested using coimmunoprecipitation with anti-RyR2 antibodies;
(H) representative Western blots and pooled data for B56a (I) and PP2AC (J), *significantly different vs. control, p,0.05, n=6. K. Local CaMKII activity
measured in samples with immunoprecipitated RyR2s (n=4). Local CaMKII activity levels and levels of PP2AC and B56a were normalized to the levels
of RyR2s.
doi:10.1371/journal.pone.0028324.g003
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PP2ACa or psiCHECK-PP2ACa-mut (i.e. the putative miR-133 binding has been mutated) luciferase reporter construct and miR-133, or negative
control miRNA mimics at the concentrations indicated. B. Alternatively, CHO cells were transfected with either the psiCHECK-PP2ACb or psiCHECK-
PP2ACb-mut luciferase reporter construct and miR-133, or negative control miRNA mimics at the concentrations indicated. Twenty-four hours
following transfection, luciferase activities were measured. Renilla luciferase activity was normalized to firefly luciferase activity and mean activities 6
S.E. from three-five independent experiments are shown (*p,0.05 vs. 0 nM).
doi:10.1371/journal.pone.0028324.g004
Figure 5. Inhibition of PP2A promotes spontaneous Ca
2+ release under condition of b-adrenergic stimulation. A, Representative line-
scan images and temporal profiles of Rhod-2 fluorescence recorded in control myocyte treated with 100 nM Iso alone, 300 nM fostriecin (30 min
preincubation), a specific PP2A inhibitor, alone, and 300 nM fostriecin plus 100 nM Iso, respectively. Cells were field-stimulated at 0.3 Hz. B,
Frequency of diastolic SCWs was calculated for myocytes treated with Iso alone (n=12), fostriecin (Fost) alone (n=11), and Fost plus Iso (n=11).
*, p,0.05 Fost plus Iso vs. Iso alone; {,p ,0.05 Fost plus Iso vs. Fost alone.
doi:10.1371/journal.pone.0028324.g005
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treatment of HF myocytes with the CaMKII inhibitor KN93
(1 mM, 15 min) significantly reduced site Ser-2030 phosphoryla-
tion levels at basal conditions, and in the presence of phosphatase
inhibitor and Iso (Fig. 6E,F). Collectively, these results indicate the
involvement of muscle-specific miRNAs in the regulation of
CaMKII-dependent phosphorylation of the RyR2 via PP2A.
Coordinated expression of miR-1 and miR-133 in
cardiomyocytes
To elucidate the specific roles of miR-1 and miR-133 in the
regulation of PP2A we infected rat ventricular myocytes with the
corresponding adenoviral constructs. After 48 hours in culture
myocytes infected with Ad-miR-133 exhibited ,1.5-fold increase
in Ca




Figure 6. Enhanced phosphorylation of RyR2 at sites S-2814 and S-2030 in HF. A, B. Representative Western blots (A) and pooled data (B)
for normalized RyR2 phosphorylation at sites - S-2030 and S-2808 and S-2814 to total RyR2 content measured in gels run in parallel. Levels of RyR2s in
HF and control cells were compared using GAPDH as loading control. *p,0.05, n=8. C.D, Representative Western blots (C) and pooled data (D) for b-
adrenergic agonist Isoproterenol dose-dependence of S-2030. Signals obtained with anti pS-2030 ab were normalized to the levels of RyR2s assessed
in gels run in parallel and normalized to maximum level of phosphorylation achieved by 30 min incubation of myocytes isolated from normal hearts
with PP1 and PP2A inhibitor Calyculin A (100 nM) and exposed to 1 mM Iso for 3 min. *{,p,0.05 vs baseline and Iso+Calyculin respectively, n=6. E,F.
Representative Western blots and pooled data illustrating sensitivity of S-2030 to phosphorylation by CaMKII in myocytes isolated from failing hearts.
Incubation with CaMKII inhibitor KN93 (1 mM, 15 min) significantly reduced S-2030 phosphorylation at basal conditions and after myocytes treatment
with Iso and Calyculin A. *p,0.05 vs no KN93, n=4.
doi:10.1371/journal.pone.0028324.g006
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2+
content (Fig. 7A,C). Accordingly, the fraction of Ca
2+ released
from SR upon electrical stimulation, i.e. the ratio of Ca
2+ transient
amplitude to the amplitude of caffeine-induced transient was 50%
higher in miR-133 infected myocytes than in control (Fig. 7D).
These results suggest that enhanced excitation-contraction cou-
pling in miR-133-overexpressing myocytes stems from increased
responsiveness of RyR2s to triggering Ca
2+, similar to what was
previously described for miR-1 overexpressing myocytes [16].
Overexpression of miR-1 or miR-133 led to a significant increase
in the frequency of pro-arrhythmic spontaneous Ca
2+ waves in
paced myocytes exposed to Iso. (Fig. 7E,F). Notably, coinfection of
myocytes with both adenoviruses did not further augment
spontaneous Ca
2+ release. qRT-PCR studies revealed that
myocytes infected with the miR-1 Adv increased not only miR-1
levels but the levels of miR-133 as well (Fig. 7H upper panel). A
similar reciprocity was detected in miR-133 infected myocytes
(Fig. 7H lower panel). Accordingly in three groups of myocytes;
infected with miR-1 only, miR-133 only and miR-1 together with
miR-133, Western blot experiments showed a similar 30%
decrease in PP2AC with respect to control. Interestingly, in
control experiments in non-muscle cells (HEK), only the miRNA
carried by its respective viral construct was detected but not its
counterpart (Fig. 7I). Taken together, these data suggest that in
muscle cells, both miR-1 and miR-133 expression levels are
coordinated.
CaMKII inhibition attenuates diastolic Ca
2+ waves
underlying arrhythmogenic afterdepolarizations in HF
myocytes
To investigate the possible involvement of CaMKII in
arrhythmogenesis in myocytes isolated from failing hearts we
examined the effects of the specific CaMKII inhibitory peptide,
ACI [31] on the generation of pro-arrhythmic spontaneous Ca
2+
waves. Myocytes were paced in the current clamp mode (at
0.5 Hz) in the presence of Iso (100 nM). In stark contrast to
control myocytes, HF myocytes exhibited spontaneous Ca
2+ waves
that caused delayed and early afterdepolarizations (Fig. 8A and
8B). Notably, introduction of the CaMKII inhibitory peptide
(ACI, 200 mM) into the pipette solution restored normal periodic
Ca
2+ cycling in HF myocytes. To further assess the requisite role of
altered CaMKII phosphorylation balance in pro-arrhythmic
alterations of Ca
2+ handling we examined the effects of the
CaMKII inhibitor KN93 (1 mM, 15 min) on spontaneous Ca
2+
waves induced on inhibition of PP2A in paced control myocytes
from normal hearts in the presence of Iso. The inhibition of
CaMKII in these experiments reversed the increase in arrhyth-
mogenic propensity caused in myocytes by a combination of Iso
and PP2A inhibition. (the number of spontaneous waves per cycle
was 0.4360.12 vs. 0.0960.09* for Calyculin A (n=20) and
Calyculin + KN93 (n=12), respectively, *statistically significant at
p,0.05, Student’s t-test). Thus, these results strongly support the




In the present study, we have investigated the possible link
between enhanced predisposition of ventricular myocytes toward
pro-arrhythmic spontaneous Ca
2+ release and altered expression
levels of two major muscle-specific miRNAs, miR-1 and miR-133
in a canine model of chronic HF. Our main finding is that the
increased expression of miR-1 and miR-133 observed in HF was
associated with reduced levels of PP2A regulatory (B56a and
B56d) and catalytic subunits. The dissociation of PP2A activity
from the RyR2 complex in HF resulted in CaMKII-dependent
hyperphosphorylation of the RyR2 and profound pro-arrhythmic
disturbances in Ca
2+ cycling and membrane potential. Our results
suggest that, in chronic HF, increased miR-1 and miR-133
expression levels lead to abnormal myocyte Ca
2+ handling through
disruption of site-specific PP2A phosphatase activity.
Our conclusions regarding the role of miR-1 and miR-133 in
HF are supported by the following specific experimental findings:
(1) pharmacological inhibition of PP2A activity in control
myocytes was sufficient to promote proarrhythmic spontaneous
Ca
2+ release during b-adrenergic stimulation; (2) enhanced levels
of miR-1 and miR-133 in HF myocytes were associated with (a)
decreased expression of B56a and B56a known to be involved in
subcellular targeting of PP2A and (b) reduced total expression
levels of catalytic subunits of PP2A, reduced total PP2A activity
and reduced levels of PP2A catalytic subunits associated with the
RyR2; (3) in HF, the miRNA-associated reduction in PP2A levels
led to significant increases in RyR2 phosphorylation at the PP2A-
dependent sites Ser-2814 and Ser-2030; and (4) the functional
consequences of pharmacological inhibition of phosphatases in
control myocytes and of the miRNA-related decreases in total and
localized PP2A activity in HF myocytes were reversed by CaMKII
inhibitors.
HF is associated with pathological remodeling of ion channels
and intracellular signaling pathways, including altered phosphor-
ylation of RyR2s [8,9]. Increased phosphorylation of RyR2s in HF
has been suggested to arise from decreased activity of RyR2
channel-associated phosphatases [10,11]. Consistent with these
previous studies we found that the RyR2 is hyperphosphorylated
at the CaMKII-dependent site, Ser-2814 (Fig. 6), and the
expression of the catalytic and scaffolding regulatory subunits
B56a and B56d of PP2A are reduced in a canine tachypacing
model of HF (Fig. 3). Additionally, in HF myocytes we found that
RyR2 phosphorylation is increased at the site Ser-2030 (Fig. 6)
which is tightly controlled by phosphatases [14] and this increase
could be effectively reversed by pharmacological inhibition of
CaMKII. In contrast, phosphorylation at the PKA site Ser-2808,
which is known to be under the specific control of PP1, remained
unchanged and coincided with unchanged levels of PP1 catalytic
subunit (data not shown). Despite similar catalytic mechanisms,
substrate recognition mechanisms for PP1 and PP2A are distinct.
Emerging evidence suggests that recognition of specific Ser/Thr
sites by PP2A involves additive effects of multiple distinct
interactions [32,33].
Recent studies have documented the importance of miRNAs in
a number of pathological processes in the cardiovascular system,
including cardiac arrhythmias [34,35,36], cardiac hypertrophy,
HF, cardiac fibrosis and ischemia [20,23,24,25,26,37,38]. MiR-
NAs are a family of small, ,21-nucleotides long, nonprotein-
coding RNAs that have emerged as key post-transcriptional
regulators of gene expression [17,18]. Of the ,1000 mammalian
miRNAs discovered thus far, several appear to be muscle-specific
and expressed in the heart, including miR-1 and -133 [28].
Genetic ablation of these two most abundant miRNAs in the heart
has been reported to result in early death in transgenic animals,
underscoring the vital importance of miR-1 and -133 for cardiac
development and function [28]. Expression profiles of miR-1 and -
133 have been shown to be dramatically altered in cardiac disease
[20,21,22,23,24,25,26,27] and are thought to play an important
role in disease-related remodeling and arrhythmia [34,35]. Here
we demonstrate, for the first time, that miR-1 and miR-133
expression is coordinated; such that an increase in the level of one
miRNA leads to increased expression of the other (Fig. 7). This
MicroRNAs and Arrhythmogenesis in Heart Failure
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each other in such a way that the combination of mRNA targets
inhibited by these miRNAs would result in pro-arrhythmic
alterations in Ca
2+ handling.
We recently reported that adenoviral-mediated overexpression
of miR-1 increases CaMKII phosphorylation of the RyR2 by
targeting the PP2A regulatory subunit B56a ˜ Importantly, the
decreased expression of B56a resulted in increased RyR2 activity
and enhanced EC-coupling and promoted arrhythmogenic
spontaneous Ca
2+-release [16]. We hypothesized that this
mechanism may be involved in RyR2 hyperphosphorylation and
arrhythmogenesis in HF [16,39]. Here we show, for the first time,
 
 
Figure 7. Overexpression of miR-1 and miR-133 increases the frequency of pro-arrhythmic spontaneous Ca
2+ waves (SCW) in rat
myocytes. A, Time dependent profiles of electrically- (field stimulation at 0.5 Hz) and 10 mM caffeine-evoked Ca
2+ transients in myocytes infected
with scrambled and miR-133 carrying Advs (MOI 100) after 48 hrs in primary culture. B,C,D. Pooled data for electrically and caffeine evoked Ca
2+
transient amplitude and fractional release in miR-133 overexpressing myocytes vs. controls. E. Representative confocal Ca
2+ images with
corresponding time dependent profiles recorded in field-stimulated (0.2 Hz) myocytes in the presence of 100 nM isoproterenol infected with miR-1
and/or miR-133 Adv. F. Pooled data for the number of SCWs per second. *Statistically significant at p,0.05 vs. scrambled, n=15–25. G.
Representative Western Blots (upper panel) and pooled data (lower panel) of PP2AC in myocytes infected with control Adv (scrambled) or miR-1, or
miR-133 or both miR-1 and miR-133; *,0.05 vs control, n=6. H. Levels of miR-1 and miR-133 in myocytes assessed by qRT-PCR. *,0.05 vs control,
n=3. I. Infection of non-muscle cells (HEK) with miR-1 does not result in increase in expression levels of miR-133 and vise versa, *p,0.05 vs control,
n=3.
doi:10.1371/journal.pone.0028324.g007
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animal model of HF [40]. Moreover, miR-1 and -133 overex-
pression was associated with reduced protein levels of the catalytic
and regulatory subunits of PP2A, increased RyR2 phosphorylation
and increased arrhythmic potential in HF myocytes. These
alterations in Ca
2+ cycling were mimicked by broad pharmaco-
logical inhibition of phosphatases (Fig. 1) and specific inhibition of
PP2A (Fig. 5) in normal myocytes, whereas specific inhibition of
CaMKII normalized Ca
2+ cycling in cells isolated from failing
hearts (Fig. 8).
The molecular mechanisms by which the expression of specific
miRNAs are regulated is poorly understood, however, it is clear
that the expression levels of miR-1 and miR-133 in the heart can
differ depending on the stages and etiology of HF [41]. Future
studies will carefully examine the dynamics of changes of miRNAs
during disease progression as well as the possible effects of various
therapeutic interventions on miRNAs expression profile. For
example, a recent report showed that b-adrenergic antagonist
(propranolol) can down-regulate miR-1 [42]. It is tempting to
speculate that the antiarrhythmic effects of chronic administration
of beta-blockers at least in part are stemming from their ability to
regulate miRNAs and thus alter phosphatase activity in cardiac
myocytes. The results presented here are also consistent with the
previously published data suggesting that a shift in phosphoryla-
tion balance toward dephosphorylation in genetically modified
mice [43] may have beneficial antiarrhythmic effects. In summary,
these results demonstrate, for the first time, that increased RyR2
phosphorylation and arrythmogenesis in HF may result from
miRNA-mediated decreases in PP2A activity. Our findings
provide a rationale for establishing muscle-specific miR-1 and -
133 as targets for antiarrhythmic therapy.
Materials and Methods
Heart Failure Model
All procedures were approved by The Ohio State University
and Rhode Island Hospital Institutional Animal Care and Use
Committees and conformed to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). A total of eight
hound type dogs of either sex (2–3 years of age) had a right
ventricular (RV) pacemaker lead implanted in the RV apex as
previously described [44]. Following recovery from the pacemaker
implant, the RV was paced at 180 BPM for 2 weeks; 200 BPM for
the next six weeks, followed by 180 BPM for the duration of the
protocol (modified Prevail 8086 pacemakers, Medtronic, Inc.,
Minneapolis, MN). Serial echocardiograms were performed at
baseline and during brief periods of sinus rhythm during the
pacing protocols, during butorphanol sedation (0.5 mg/kg, IM)
[44]. A group of eight hound type dogs of either sex (2–3 years of
age) served as controls.
Myocyte cell isolation, cell culturing and transfection
with adenoviruses
Dogs were euthanized with intravenous sodium pentobarbital or
sodium thiopental, followed by rapid removal of the heart as
previously described [44]. Hearts were rapidly excised via
thoracotomy and perfused with cold cardioplegic solution
(containing 5% glucose, 0.1% mannitol, 22.4 mM NaHCO3
and 30 mM KCl) injected into the coronary ostia. The left
circumflex artery was cannulated for left ventricular mid-
myocardial myocyte isolation. Following the washout of blood
from the heart, collagenase (Worthington type II, 0.65 mg/ml)
and protease-free bovine serum albumin (BSA) (0.65 mg/ml) were
added to the perfusate (100 ml). After 30–45 min of collagenase
perfusion, the digested mid-myocardial section of the lateral wall
of the left ventricle was separated from the epicardial and
endocardial sections; digested tissue was shaken in a water bath at
37uC for an additional 5–10 min. The myocytes were divided for
molecular, biochemical, and electrophysiological assays and stored
at room temperature until use. Isolation of rat ventricular
myocytes was performed as previously described [45]. Isolated
myocytes were plated on laminin-coated glass coverslips in serum-
free medium 199 supplemented with (in mM): 25 NaHCO3,5
creatine, 5 taurine, 10 U/ml penicillin, 10 mg/ml streptomycin,
and 10 mg/ml gentamycin (pH 7.3). Cells were cultured at 37uC
in a humidified atmosphere with 95% air/5% CO2. After 2 hours,
unattached cells were removed and myocytes were infected with
adenoviruses at multiplicity of infection (MOI) 100 and cultured
for 36–48 hours before analysis. At such conditions culture-
dependent changes in myocyte structure and function are minimal
[46]. Recombinant adenoviruses were constructed, propagated,
and tittered as previously described [24]. Briefly, pBHGlox-
DE1,3Cre (Microbix), including the DE1 adenoviral genome, was
co-transfected with the pDC shuttle vector containing the stem–
loop sequence of the mouse miR-1-2 and miR-133a gene, into 293
 
Figure 8. Inhibition of CaMKII activity attenuates pro-arrhythmic spontaneous Ca
2+ waves in HF myocytes. A. Representative confocal
Ca
2+ images, with corresponding time dependent profiles (bottom) and membrane potential recordings (top) in myocytes isolated from normal and
failing hearts in the presence of 100 nM Iso. B. Pooled data for a number of spontaneous Ca
2+ waves per cycle. *p,0.05, n=5–10.
doi:10.1371/journal.pone.0028324.g008
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homologous recombination, the test genes integrate into the E1-
deleted adenoviral genome. The viruses were propagated in 293
cells and purified using CsCl2 banding, followed by dialysis against
20 mM Tris buffered saline with 2% glycerol. Tittering was
performed on 293 cells overlaid with DMEM plus 5% equine
serum and 0.5% agarose.
Ca
2+ imaging and electrophysiology
Action potentials (APs) were recorded using the whole-cell patch
clamp technique. The patch-clamp system was based on Axopatch
200B amplifier and DIGIDATA 1322A interface (Axon Instru-
ments, CA). The external solution consisted of (mM): 140 NaCl,
5.4 KCl, 2.0 CaCl2, 0.5 MgCl2, 10 HEPES, and 5.6 glucose
(pH 7.4). Patch pipettes were filled with the following solution
(mmol/L): 90 K-aspartate, 50 KCl, 5 MgATP, 5 NaCl, 1 MgCl2,
0.1 Tris GTP, 10 HEPES, and 0.06 Fluo-3 (Molecular Probes,
OR) (pH 7.2). The APs were evoked by application of 4-ms-long
voltage pulses with amplitude 50% above the threshold level.
Intracellular Ca
2+ imaging was performed using an Olympus
Fluoview 1000 and Leica SP5 confocal systems. Fluo-3 was excited
by the 488 nm line of an argon-ion laser, and the fluorescence was
acquired at wavelengths .510 nm. Rhod-2 was exited by 543 nm
laser and the fluorescence was acquired at 590–690 nm wave-
lengths.
Western Blot analysis, coimmunoprecipitation and
CaMKII activity
Western blot analyses were performed as previously described
[16] using RIPA buffer supplemented with phosphatase, calpain
and protease inhibitors (Sigma, St Louis MO) and 1 mM Calyculin
A (Calbiochem, Darmstadt, Germany) which was directly added
to the cells after treatment to stop phosphorylation/dephosphor-
ylation and the samples were instantly frozen in liquid N2. Cell
lysate proteins were subjected to 4% to 20% SDS-PAGE and
blotted onto nitrocellulose membranes (Bio-Rad Labs, Richmond
CA). Primary antibodies used: anti-phospho-RyR2-S2808 and
anti-phospho-RyR2-S2030 were raised against CRTRRIS(P-
O4)QTSQ-CONH2 and (CG)TIRGRLLS(PO4)LVEKVTYLK-
K-CONH2, respectively (Phosphosolutions, Aurora, CO). Anti-
phospho-RyR2-S2814 was a gift from Dr. X. H. Wehrens (Baylor
Coll. of Med., TX). For RyR2 phosphorylation, cells were studied
before being lysed and were periodically field stimulated at 1 Hz
for 1 min in Tyrode solution. Anti-RyR2, was from Thermo-
FisherScientific; anti-PP2A B56a, from Millipore (Billerica, MA);
anti-PP2A B56d from Abcam (Cambridge MA); anti-PP2AC from
Calbiochem (Darmstadt, Germany); anti-GAPDH used as a
loading control was from Abcam (Cambridge, MA). For
coimmunoprecipitation the samples were incubated with protein
A Sepharose beads at 4uC for 1 h, after which the beads were
washed three times with buffer. Proteins (40–60 mg) were
separated on SDS PAGE and blotted onto nitrocellulose
membranes. Membranes were incubated for 1–2 hour at room
temperature with primary anti-RyR2, anti-B56a or anti-PP2AC
antibodies. Protein bands were visualized using the Super Signal
West Pico kit (Pierce, IL).
Local CaMKII activity was measured in immunoprecipitated
RyR2s samples using Cyclex non-radioisotopic kit according to
manufacturer’s instructions (CycLex Co., Columbia, MO). To
perform the relative semi-quantitative immunoassay, the samples
(10–20 mg) were diluted in Kinase Buffer, pipetted into microplate
wells precoated with CaMKII substrate Syntide 2 and allowed to
phosphorylate the bound substrate in the presence of Mg
2+ and
ATP. The amount of phosphorylated substrate was measured by
binding with peroxidase conjugate of antibody that specifically
detects phosphorylated substrate. The color was quantified by
measuring absorbance at dual wavelength of 450/540 nm using
microplate reader (Synergy MX, BioTeck Instruments Inc.,
Winooski, VT).
Protein Phosphatase 2A activity assay
Tissue samples from the left-ventricle free wall were homoge-
nized in buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 10% glycerol containing 1 mM DTT, 1 mM PMSF with
complete protease inhibitors (Roche Diagnostics, Indianapolis, IN)
using Tissue Tearor (Biospec Products, Inc). The homogenate was
centrifuged at 15,0006g for 15 min. The clear supernatant was
depleted of free phosphate by using Sephadex G-25 resin spin
columns (Promega, Madison, WI). Protein Phosphatse 2A activity
was determined using the serine/threonine phosphatase assay
system microplate assay kit (Promega, Madison, WI), which
determines the amount of free phosphate generated in a reaction
by measuring the absorbance of a molybedate: malachite green:
phosphate complex. Briefly, appropriate phosphate standards
diluted in phosphate-free water, 56PPase reaction mix and 1 mM
phosphopeptide were added to a flat-bottom 96-well plate (total
volume 50 ml). Reaction was initiated by adding protein sample
(15–30 mg) following incubation at room temperature for 15–
20 min. The reaction was stopped by adding equal volume (50 ml)
of Molybedate dye, followed by incubation for 15–30 min at room
temperature. Optical density of the molybedate: malachite green:
phosphate complex was read using a plate reader with a 630 nm
filter. Specific activity is expressed as picomoles of phosphate
released/min/mg protein.
Luciferase reporter constructs
A 1312-bp fragment encompassing the entire PP2A catalytic
subunit a (PP2ACa)3 9-untranslated region (39-UTR) was PCR-
amplified utilizing the following sense (59- TGA AAT TTT AAA
CTT GTA CAG TAT TG -39) and antisense (59- GGT GAA
TGT ACA TAA GAC TAA ATC -39) primers. A 599-bp
fragment encompassing the majority of the PP2A catalytic subunit
b (PP2ACb)3 9-UTR was PCR-amplified utilizing the following
sense (59- ATT TCT CCT GGG AAA CCT GCC TTT G -39)
and antisense (59- GTT TAT TTG CTG AGT ACA CCA AAT
AGG -39) primers. Both were amplified using standard procedures
and a proofreading polymerase (Platinum Pfu, Invitrogen). Human
male genomic DNA (Promega) was used as template. Following
the manufacturer’s protocol, the PCR product was treated for
10 minutes with Taq polymerase. The PCR product was
subsequently subcloned into the pCR
TM2.1 vector following the
manufacturer’s protocol (Invitrogen). Plasmid DNA was subse-
quently isolated from recombinant colonies and sequenced to
ensure authenticity. The PP2ACa and PP2ACb 39-UTR inserts
were removed from the pCR
TM2.1 plasmid by EcoRI digestion.
The fragments were subsequently gel purified, filled in and blunt-
end ligated into a filled-in XhoI site that is located downstream of
the Renilla luciferase (r-luc) reporter gene (psiCHECK-2
TM,
Promega). The authenticity and orientation of the inserts relative
to the Renilla luciferase gene were confirmed by dideoxy
sequencing. The resulting recombinant plasmids were designated,
psiCHECK/PP2ACa and psiCHECK/PP2ACb.
The mutant reporter construct psiCHECK/PP2ACa-mut was
generated by utilizing the psiCHECK/PP2ACa plasmid as
template and mutating the putative miR-133 recognition site
(located at 122–128 bp) harbored in the PP2ACa 39-UTR using
the QuikChange site-directed mutagenesis kit (Stratagene). Briefly,
a forward miR-133 mutagenic primer (59- AAC TTG TTT TCA
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and a complementary reverse miR-133 mutagenic primer (59-
ATT TTT ATA TGG CAC ATC TAA ACC AGG ATG TGA
AAA CAA GTT-39), were synthesized and utilized in a PCR
experiment as described by the manufacturer. The mutant
reporter construct psiCHECK/PP2ACb-mut was generated by
utilizing the psiCHECK/PP2ACb plasmid as template and
mutating the putative miR-133 recognition site (located at 139–
145 bp) harbored in the PP2ACb 39-UTR using the QuikChange
site-directed mutagenesis kit (Stratagene). Briefly, a forward miR-
133 mutagenic primer (59- CAT TAA ACC ACA TCA TCC
TGG TTT TGT GCC ATA CTA ATG ATG -39) and a
complementary reverse miR-133 mutagenic primer (59- CAT
CAT TAG TAT GGC ACA AAA CCA GGA TGA TGT GGT
TTA ATG -39), were synthesized and utilized in a PCR
experiment as described by the manufacturer. Mutated sequence
is shown in bold print. The amplification reactions were treated
with DpnI restriction enzyme to eliminate the parental template
and the remaining DNA was used for transformation. The
mutation of the miR-133a-1 seed binding sites was confirmed by
dideoxy chain termination sequencing. Finally, transformed
bacterial cultures were grown and each reporter construct was
purified using PureLink
TM Hipure Plasmid Maxiprep Kit
(Invitrogen).
Transfection and Luciferase assay
CHO cells were purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplement-
ed with 10% fetal bovine serum (HyClone Laboratories, Logan,
UT), 16 antibiotic-antimycotic, and 0.0175 mg/ml L-proline
(Sigma). miR-133a-1 and negative control mimics (partially
double-stranded RNAs that mimic the Dicer cleavage product
and are subsequently processed into their respective mature
miRNAs) were obtained from Dharmacon (Lafayette, CO).
Transfection of CHO cells with small RNAs was optimized
utilizing Lipofectamine 2000 (Invitrogen) and a fluorescein-labeled
double-stranded RNA oligomer designated BLOCKiT
TM (Invi-
trogen). Once conditions were optimized, CHO cells (approaching
100% transfection efficiency) were transfected with the luciferase
reporter constructs described above and the appropriate miRNA
precursor as indicated. After 24 hrs, CHO cells were washed and
lysed with Passive Lysis Buffer (Promega), and firefly and Renilla
luciferase activities were determined using the Dual-Luciferase
Reporter Assay System (Promega) and a luminometer. Renilla
luciferase expression in the psiCHECK vector is generated via an
SV40 promoter. Additionally, the psiCHECK-2 vector possesses a
secondary firefly reporter expression cassette which is under the
control of the HSV-TK promoter. This firefly reporter cassette has
been specifically designed to be an intraplasmid transfection
normalization reporter; thus when using the psiCHECK-2 vector,
the Renilla luciferase signal is normalized to the firefly luciferase
signal.
Real-time PCR
Total RNA was isolated from canine control and HF myocytes
with Trizol reagent (Invitrogen). The RNA was subsequently
treated with RNase-free DNase I, and mature miR-1 and -133
were quantified by utilizing TaqMan microRNA assay kits specific
for each miRNA (Applied Biosystems, Foster City, CA) as
previously described [16]. Briefly, 100 ng of total RNA was
heated for 5 min at 80uC with 2.5 mM of the miR-1 or -133 and
RNU48 antisense primers, followed by 5 min at 60uC then cooling
to room temperature. The resulting solution was added to a
cocktail and reverse transcription was performed in a 20 ml
reaction according to the manufacturer’s recommendations
(Applied Biosystems). Quantitative real-time PCR (20 ml total
reaction) was performed by using 5 ml of a 1:5 dilution of cDNA.
Results were analyzed using the 2
2DDCt relative quantification
method [47]. For each target miRNA, DCt was calculated by
subtracting their average Ct value from the average Ct value of the
small noncoding RNA, RNU48.
Data analysis
Echocardiographic data are presented as mean 6 SD.
Differences in echocardiographic parameters were evaluated by
unpaired t-tests. Statistical significance of Ca
2+ measurements and
biochemical analyses were determined by one-way ANOVA and
Student’s t-test where appropriate and presented as mean 6 SE.
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